Clinical Products to test-market ExtendBar at So. Cal. retailers
LOS ANGELES Clinical Products on Monday announced the test-market launch of ExtendBar into southern California retailers, including Albertson’s, Ralph’s and Walgreens.
“We believe partnering with Albertsons, Ralphs and Walgreens is a great opportunity for more people to experience the ExtendBar brand and what so many of our loyal, long-time customers have discovered about us,” stated Vijay Chauhan, president of Clinical Products.
ExtendBar is a snack bar specifically formulated to help control blood sugar for up to nine hours, the company claims.
The bar is formulated using slowly metabolizing carbohydrates to extend the release of glucose into the bloodstream.
The product had been developed by Francine Kaufman, past president of the American Diabetes Association.
The Discovery Health Channel recently featured Kaufman’s tour of the world in its documentary “Diabetes: A Global Epidemic.”
Merz announces distribution of Mederma scar management w/sun protection
GREENSBORO, N.C. Merz Pharmaceuticals will begin distributing its Mederma Cream + SPF 30, which helps reduce the appearance of scars while protecting them from the sun, in March, the company announced Friday.
“In nationwide discussions with consumers who are affected by scars, we identified an unmet need in the marketplace for a better scar management product which offers the sun protection that consumers expect,” stated Javier Perez, product manager for Mederma.
New scars are susceptible to becoming discolored by the sun, the company noted, citing dermatologist to minimize sun exposure to new scars.
Study pinpoints best aspirin dosage for heart attack victims
DALLAS While many consumers at risk of heart disease supplement with 81 mg of aspirin daily, a recent study published in this week’s edition of the American Heart Association journal Circulation found that double that dose significantly reduces mortality in people who are suffering from a heart attack.
The International Study of Infarct Survival trial demonstrated that treatment with 162.5 mg aspirin reduces morbidity and mortality in heart attack patients, at least as much as 325 mg of aspirin, but is not associated with a significant increase in risk of moderate or severe bleeding as is the case with the higher dose of aspirin.
Presently, the most common initial dose of aspirin in the immediate aftermath of a heart attack is 325 mg.
On the basis of these data, the American College of Cardiology, American Heart Association and European Society of Cardiology gave a class I level of evidence A to immediate use of 162 mg of aspirin, which is the strongest recommendation backed by strong evidence of efficacy as ranked by the organizations.
“Although these data are non-randomized, they suggest that for the first dose of aspirin, 162 mg may be as effective as and safer than 325 mg for the acute treatment of [a heart attack],” the study concluded.